BeyondSpring Inc.

BeyondSpring Inc. announced significant leadership transitions, effective July 1, 2026, to deliver focused execution on its DUBLIN-4 confirmatory Phase 3 program for Plinabulin. Dr. Lan Huang will transition from her role as CEO to Chair of the Board, forfeiting unvested equity, to dedicate her executive focus to SEED Therapeutics. Min Qiu is appointed Chief Executive Officer and Na Li as Chief Financial Officer, while Dr. Jiangwen Majeti is named Vice Chair of the Board, receiving a grant of 100,000 share options.

BeyondSpring Inc. announced a leadership transition effective July 1, 2026, appointing Min Qiu as Chief Executive Officer and Na Li as Chief Financial Officer. Dr. Jiangwen (Jen) Majeti was named Vice Chairman. Founder Dr. Lan Huang will remain Chairman of BeyondSpring while dedicating her executive focus to SEED Therapeutics. These changes aim to accelerate the DUBLIN-4 confirmatory Phase 3 program for Plinabulin and expand its global partner and investor base.

BeyondSpring Inc. announced updated positive efficacy and safety data from its investigator-initiated Phase 2 303 Study of pembrolizumab plus Plinabulin and docetaxel for metastatic non-small cell lung cancer (NSCLC) patients with acquired resistance to immune checkpoint inhibitors. The data, presented at ASCO 2026, showed a median Progression-Free Survival (PFS) of 7.0 months and a 24-month Overall Survival (OS) rate of 58.0%. The combination demonstrated durable survival benefit, good tolerability, and immune activation, suggesting Plinabulin's potential to address unmet needs in this patient population.

BeyondSpring Inc. announced an upcoming poster presentation of its investigator-initiated Study 303 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase 2 study evaluates Plinabulin, Docetaxel, and Pembrolizumab in 47 patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on PD-1/PD-L1 inhibitors. The presentation will cover the efficacy and immunophenotyping of this triple combination therapy.

BeyondSpring Inc. reported a net loss attributable to the company of $2.16 million for the first quarter of 2026, a significant decline from a net income of $4.48 million in the prior year period. This shift was primarily driven by a loss from discontinued operations of $4.32 million in Q1 2026, compared to a gain of $3.75 million in Q1 2025 which included a gain on sale of subsidiary interests. The company's total shareholders' deficit widened to $30.35 million as of March 31, 2026.

BeyondSpring Inc. reported a net loss of $2.4 million from continuing operations for Q1 2026, an improvement from $2.6 million in Q1 2025. However, the overall net loss attributable to BeyondSpring Inc. was $2.16 million, a significant change from net income of $4.48 million in Q1 2025, largely due to a $4.3 million loss from discontinued operations. The company also provided a corporate update, highlighting positive preclinical data for Plinabulin and the advancement of SEED Therapeutics' ST-01156 into Phase 1 clinical development.

BeyondSpring Inc. reported new preclinical data at AACR 2026, showing Plinabulin significantly improves complete response rates and survival when combined with leading ADC drugs, both with and without immunotherapy. The data indicates Plinabulin enhances both efficacy and tolerability by activating GEF-H1, which matures immune cells, replenishes blood cells, and disrupts tumor blood supply. This strengthens the scientific rationale for Plinabulin's combination potential, extending its reach across the treatment landscape and supporting the planned DUBLIN-4 confirmatory Phase 3 trial.